Acumen Pharmaceuticals, Inc.
ABOSHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeAcumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. With a market capitalization of $143.2M, it sits in micro-cap territory. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers.
Market Cap
$143.2M
Beta
0.33
P/E (TTM)
—
P/E (Fwd)
-1.38
EPS (TTM)
$-1.64
EPS (Fwd)
$-1.43
ROE
-120.5%
ROA
-45.8%
Cash
$110.2M
Total Debt
$31.6M
Free CF
-$56.5M
52W Change
-10.0%
Annual Financials
Cash vs Debt
Where ABOS stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ABOS finished 28.92% below its 150-day moving average ($2.49) and 29.20% below its 200-day moving average ($2.50). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ABOS overbought or oversold?
At the October 20, 2026 close, ABOS's RSI(14) was 27.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $110.2M in cash comfortably exceeding the $31.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$56.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -120.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The relatively low beta of 0.33 suggests ABOS is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, ABOS has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing ABOS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.